A federal appeals court last week rejected a request from marijuana opponents to temporarily block the Trump administration from moving forward with broader marijuana rescheduling while their lawsuits are considered, keeping the process alive. The ruling does not guarantee marijuana will move from Schedule I to the more lenient Schedule III, and the court consolidated three challenges to the broader rescheduling proposal and directed the parties to submit a proposed briefing schedule. The Trump administration has already placed FDA-approved marijuana products and qualifying state-licensed medical marijuana products into Schedule III, while a separate DEA process considers the broader removal of marijuana from Schedule I. Tilray Brands, which is already a major international medical cannabis supplier, reported record revenue of $915 million in fiscal 2026 ended May 31, finished the year with about $235 million in cash, restricted cash and marketable securities, reduced net debt to just $700,000, and now expects adjusted EBITDA of $68 million to $75 million in fiscal 2027. International medical cannabis revenue rose 34% in fiscal 2026, and management has identified U.S. rescheduling as an opportunity to eventually expand Tilray Medical into the American market.
Tilray IncTilray reported record $915 million fiscal 2026 revenue, cut net debt to $700,000, and guided FY2027 adjusted EBITDA of $68-75 million
NVIDIA Corporation